Client zone

ANGLE device shows promise in assessing melanoma patients

Parsortix was also shown to be superior to other methods at picking up the tell-tale signs of cancer

Researchers in Western Australia using the Parsortix liquid biopsy system have found another use for the ANGLE PLC (LON:AGL) cancer detection device.

A team at Edith Cowan University in Perth deployed the technology to monitor people with melanoma and were able to sort them into high risk and low-risk groups.

This has opened the possibility of assessing the prognosis and tailoring the treatment approach “taking into account disease status”, ANGLE investors were told.

Parsortix was also shown to be superior to other methods looked at by the Edith Cowan team at picking up the tell-tale signs of cancer assessed.

“This work clearly demonstrates the promising clinical utility of the Parsortix system for metastatic melanoma prognostication and monitoring treatment response,” said Elin Gray, an associate professor at the university.

“We now intend to progress our work with Parsortix to identify ways in which we can improve the treatment of melanoma patients.”

ANGLE chief executive Andrew Newland said the latest update revealed another great example of Parsortix customers developing new cancer applications for the device.

“Melanoma is an important opportunity for future use of Parsortix,” he added.

Referral Scheme

Candidate Tools

Join our Mailing list

G2 Academy

Contact Us

We offer a national recruitment service from our Surrey head office, please see contact details below.

Head Office

PM House,
Riverway Estate
Old Portsmouth Rd

T: 01483 910 940

  • 16
  • Aug 2021

Gates & Soros buy UK-based Mologic: A social enterprise to improve global healthcare

Read More

for Us

Find out More